CaP CURE 2002 Review Contents

From the Chairman 4

From the CEO 6

Year in Review 8

Funding Research 12

Collaboration 22

Raising Money 25 and Awareness

Research Awards 32

Leadership 38

Dr.Ward “Trip” Casscells Professor Gerald Haslam Diagnosed with prostate cancer at age 48. Diagnosed with prostate cancer at age 60. Patient profile on page 10. Patient profile on page 30. William Clapp Diagnosed with prostate cancer at age 63. Patient profile on page 20. Prostate cancer affects everyone, not just men. Whe n a man gets pros t a t e cancer, it cha n ge s his life. And that affects everyone close to him — friends and family, men and women. That’s why on our cover we have shown the faces of many people — fathers, mothers, brothers, sisters, children, physicians, scientists, and others. They are as committed as we are to finding better treat- ments and, eventually, a cure.

Family histories and genes may hold the key to solving part of the prostate cancer puzzle. When a man gets prostate cancer, it affects everyone close to him. A man is one-third more likely to get pros t a t e cancer than a woman is to get breast cancer.

Prostate cancer is the most common non-skin cancer in America, striking 220,000 new men each year. There is one new case every 2 ½ minutes.

As baby boomer men reach the target zone for prostate cancer, beginning at age 50, the number of new cases is projected to increase dramatically. By 2015, there will be more than 300,000 new prostate cancer cases each year, a 50% increase.

Stua r t Hol d en ,M . D. , PCF medical direc tor , is surrounded by PCF competitive awards applications.The PCF originated a “fast-track” grant-application process Dr. Andrew von Eschenbach, director of so researchers could devote their time to the National Cancer Institute,is the only advancing science rather than pleading cancer survivor ever to hold this office. for funds and completing seemingly Dr. von Eschenbach has contributed to the endless forms. PCF’s scientific mission since its inception. Since 1993, the Prostate Increasing Public Awareness Cancer Foundation has: Recent scientific advances, •Raised approximately $200 million. many driven by Prostate Cancer Foundation-funded researchers, •Funded more than 1,100 critical are more promising than ever. research projects in 100 research centers around the world. We changed our name from CaP CURE to the Prostate Cancer •Recruited talented scientists. Foundation to increase public •Helped to increase annual govern- awareness of our role in harnessing ment funding from $25 million to society’s resources to defeat this more than $500 million. deadly disease.

•Greatly increased public awareness, The need remains great. Your help which encouraged millions more has never been more important. men to be tested.

•Helped to increase the number of prostate cancer drugs under development by 50%.

The PCF hosted its 2001 New York Dinner, From left: Debbie Black, Ann Tenenbaum, a star-studded, fund-raising event at the Tom Lee, Rupert Murdoch, Whoopi Waldorf-Astoria Hotel. Hosted by Whoopi Goldberg, Joe Torre, Mickey Tarnopol, Goldberg, the dinner honored the Mack Mike Milken and David Foster. brothers: Bill, David, Earle and Fred.

3 A Passionate Pursuit

If you’re old enough to remember reasons my brother and I formalized the day President Kennedy was our philanthropy in 1982 by estab- assassinated, you’ll never forget lishing the Milken Family Medical where you were and what you were Foundation with a commitment to doing.Six years later, you were advancing medical research. We proba b ly watching TV and remem b er established a program of awards who watched with you when men for young cancer researchers so first landed on the Moon. More they could afford to continue their Cancer isn’t something I think recently, the tragedy of September laboratory investigations. about once in a while — it’s very 11th is undoubtedly seared in your Twenty-one years separated my immediate, very personal, and memory. And if you, like nearly mother-in-law’s diagnosis from the one and a half million Americans in my thoughts constantly. day in 1993 when my doctor told me, each year, ever heard the words “You have prostate cancer.” Over “You have cancer,” you’ll always those two decades, my conversations remember the moment. with hundreds of doctors — both as Few families avoid cancer. Thirty- a philanthropist and as a patient one years ago, my mother-in-law advocate — made me feel about as learned she had breast cancer. A few well informed as a layman can be on years later, my father was told he the complex topic of cancer. So the had melanoma. Eventually, this shock of learning I had cancer was disease claimed 10 members of my compounded by learning how little family. So cancer isn’t something I information was available about think about once in a while — it’s prostate cancer. Not only was my very immediate, very personal, prognosis poor — the cancer had and in my thoughts constantly. It escaped my prostate and was too changed the course of my life long advanced for surgery — but informa- before I was diagno s ed . It’s one of th e tion about my medical options was

Gen. Norman Schwarzkopf joined Mike Milken in 1998 to address several hundred tho usand marche rs on the Mal l in Was h i n g t on D.C . at THE MARCH: Coming Together to Conquer Cancer. Mike and PCF honorary board member Sydney Kimmel hel p ed organ i z e the event . Gen .S chwar z k opf is a prostate cancer survivor.

4 scarce. In 1993,most experts documented in this Annual Report. support for prostate cancer studies. thought the prostate cancer death But the most important change is We ensure that the scientists rate would rise sharply over the in the number of prostate cancer working at the very edge of science next decade as baby boomers aged. deaths, which have been kept well have the resources they need. They Yet with little financial support or below the pessimistic projections of share our sense of urgency, racing public interest, prostate cancer 1993. Also, because of better treat- against time to eliminate a disease res e a r ch was cons i d ered a backw a t er ments, survivors enjoy an improved that currently takes an American life of medicine. quality of life. Everyone who has every 18 minutes. worked so hard in this effort can The Prostate Cancer Foundation We need your support to fast- take a large measure of satisfaction (f orme rly CaP CURE) was establi s h e d forwa r d this que s t . I beli e ve fervent l y from the results. But despite all that with more in mind than accelerating that the goal is attainable when has been achieved, there’s concern a cure for prostate cancer. From the brilliant, dedicated researchers and about the future. Some 70 million beginning, we aspired to change passionate advocates come together Americans are reaching the age the face of cancer research and to with the rig ht res o u r ces . We just want when the rate of cancers begins to produc e res ults that could help peopl e to get there sooner rather than later. rise quickly. As Prostate Cancer suffering from a broad range of Thank you for helping.Thank you Foundation Vice Cha i r man and serious diseases. We never saw the for expressing your passion for life! CEO Leslie Mich el s o n explains process as a zero-sum game where on pages 6–7,the number of new increased funding for one disease prostate cancer diagnoses will soon diminished support for others. grow by as much as 50% if nothing Rather, it has always been one of else changes. our key goals to increase the size of Michael Milken the research pie in ways that would This Annual Report is both a Founder and Chairman bene fit the grea t est num b er of peopl e . review of past progress and an appeal for your involvement in our The changes that the Prostate continuing effort. The Prostate Cancer Foundation has helped Cancer Foundation is the world’s bring about over the past decade are largest philanthropic source of

Houston Astros owner Drayton McLane joined Mike Milken in the fight against pros t a t e cancer dur ing the Pros t a t e Cancer Foundation’s CaP CURE Home Run Challenge. Each year,Major League Baseball,the Major League Baseball PCF founder and chairman Mike Milken Washington, D.C. Both the Prostate Cancer Players Association,the Prostate Cancer (left) and Richard Pazdur, M.D.,director of Foundation and von Eschenbach advocated Foundation,and fans nationwide raise the FDA’s division of oncology drug products, a systems approach to cancer research and money to fund prostate cancer research listen to Andrew von Eschenbach,M.D., the search for a cure, requiring a close based on home runs hit in 60 ball games director of the National Cancer Institute working relationship between the NCI during the week before Father’s Day. (NCI), during the Prostate Cancer and academic and private researchers. Foundation’s 2002 Scientific Retreat in

5 Letter from the CEO

The National Cancer Institute’s 2003 and a cure to prevent this tragedy. projections unfortunately confirm When we began, efforts to find a what our epidemiologists predict. cure were at a standstill. Scientists This yea r , the num b er of ne w pros t a t e had few sources of funding and cancer cases in the U.S. will increase little reason to engage in prostate to 220,000. Prostate cancer is now cancer research. Federal funding the most common non-skin cancer was minimal and no pha rm a ceutic a l in Ame ric a . It accounts for one - t h i r d or biotech companies were focused 100% of al l major cancers in men — more on it. Men facing prostate cancer 78% than twice the next most common. had few good weapons to fight the One in six men will get cancer in disease and little hope that new their lifetime. treatments would become available before the disease took its toll. 50% It gets worse. As the baby boomer me n rea ch the target age for pros t a t e The Prostate Cancer Foundation 22% cancer, beginning at age 50, the has become the world’s largest annual incidence will increase to philanthropic source of funding 300,000 and the annual death rate for prostate cancer research. We 0% will reach 50,000 by 2015. Prostate are focused on finding a cure. Prostate Other Major cancer is not only distressingly With generous support from our Cancer Disease Foundation Philanthropies common; it is also the cancer with many committed donors, we have the largest expected increase in the supported some 1,100 research Percentage of Funds next decade. Unfortunately, few projects in 100 research centers Dedicated to Scientific people realize the significance of around the world since 1993. We and Medical Research this disease. invest 78 cents of every dollar we raise on medical and scientific For the past decade, the Prostate research. That is more than three Cancer Foundation has been times the averag e amount spent working tirelessly to accelerate by the other major health-care the discovery of better treatments philanthropies.

Age-Specific Probability of Diagnosis of Prostate Cancer Prostate cancer attacks with remarkable aggression beginning at age 50.

6 In the past five years, the number •Infuse the entire system with a Although the progress in finding of prostate cancer drugs under greater sense of urgency and better treatments has been dramatic, development has increased 50%. accountability; and the impending increase in incidence Federal and corporate funding of makes the need greater than ever. •Increase our support for bold, research has increased dramatically Fortunately, recent advances in high-impact initiatives. and new experimental strategies science have made the opportunities now offer the promise of turning We face special challenges in our greater than ever as well. With your pros t a t e cancer from a life- t h re a t eni n g effort to harness more of society’s support, we will be able to pursue disease into a treatable disorder. We resources to fight prostate cancer, more of these opportunities and have been there every step of the however. First and foremost,there hasten the day when prostate cancer way, prodding government policy is little public recognition of the is merely a sad memory. makers to provide more resources, gravity of this disease. Few people and igni t ing an exp l o s i o n of sc i en ti f i c realize that a man is one-third more inquiry by researchers in academic likely to get prostate cancer than a centers, biotechnology firms, and woman is to get breast cancer. Leslie D.Michelson pharmaceutical companies. We Second, this disease attacks men, Vice Chairman and CEO work closely with these scientists a tough group to get motivated to to accelerate the development of prevent a future health problem. new treatments. Many men characteristically refuse to confront health issues until they While we wil l conti n ue our historic a l are compelled to do so and are efforts, now we must also: particularly reluctant to deal with • Identify and act on specific oppor- sensitive issues related to sexual tunities to accelerate the biomedical health. To address these challenges, research and development process we are launching communications in prostate cancer; and other programs to raise public awareness and educate men and •Im prove the ef f i c i ency and ef fec- their families. tiven e s s of work funded by others;

New Cancer Cases (in thousands) Prostate cancer is the most common and most rapidly increasing cancer.

7 Prostate Cancer Foundation

Year in ReviewSince its inception in 1993, the Prostate Cancer Foundation (PCF) has become a model for other philanthropies, simplifying and speeding the grant- application process, organizing centers of excellence, bringing togeth e r exp ertise from all corne rs of the scient ific commu n i t y, and encouraging close collaboration among research leaders. The PCF has helped to nurture the best talent in medical research institutions around the world and broken down ba r rie rs betw een the laborat ory and the cli n i c , he lping patien t s receive state-of-the-art treatments sooner. Our efforts have contributed to a 50% increase in the number of prostate cancer drugs under development in the past five years and a 20-fold increase in government funding of prostate cancer research over the past 10 years.

Members of the PCF Therapy Consortium meet regularly to address major issues that impede progress in clinical development of PCF volunteers Ferne Milken, Sybil Gordon new treatments.The Therapy Consortium and Elly Levin proudly wear their “CURE” comprises eight centers of excellence where hats while putting together information leading medical oncolo g ists wor k on improved packets about prostate cancer. PCF board member Mickey Tarnopol prostate cancer treatments. and his wife, Lynne, were the benefit co- chairs for the 2001 New York Dinner at the Waldorf-Astoria Hotel in New York. The Tarnopols helped make the PCF dinner a great success.

8 The Prostate Cancer Foundation is • Forming a Therapy Consortium the world’s largest philanthropy of eight leading prostate cancer supporting prostate cancer research. research centers;

• Creating the largest database of The PCF has earned wide- fa m i ly - c lus t ered pros t a t e cancer cases; spread respect by: • Creating a tissue bank and animal •Attracting and aggregating a model network; and critical mass of talented and dedicated scientists conducting •Fostering collaboration among aca- basic and translational research; demic, corporate, and governmental researchers through the annual PCF • Creating a rapid-response, risk- Scientific Retreat and other forums. taking funding system that reduces bureaucracy and accelerates research while maintaining scientific rigor;

•Raising awareness of the need for more prostate cancer research funding by government agencies that have increased appropriations from roughly $25 million in 1993 to more than $500 million today;

Since 1996,the PCF has partnered with Major League Baseball and the Major League Baseball Players Association in the Prostate Cancer Foundation CaP CURE Safeway, one of the largest food retailers in 15,000 checkout stands in all 1,600 Home Run Challenge. With support from North America, partnered with the PCF Safeway stores in the U.S. Employees Major League teams, coaches, players, for a third year in a row to raise money also participated in internal fundraising managers and umpires,the HRC has and awareness. Steve Burd,Safeway’s drives to boost proceeds. In 2003, the rai s ed more than $18 million for pros t a t e president and chief executive officer, led a campaign raised more than $2.5 million cancer research. company-wide campaign that included for prostate cancer research. poi n t - of - pu r cha s e prom o tions at more than

9 Patient Profile

Dr. Ward “Trip” Casscells Dr.Casscells immersed himself in gri m .P C F- f u n ded res e a r ch program s Diagnosed with prostate the available state-of-the-art treat- like this have shown that integrated cancer at age 48. ments for his condition. He and his treatment approaches can help wife , Rox a n n e ,s aw Drs. Chri s t ophe r keep prostate cancer at bay for years. Dr.Ward “Trip”Casscells, an inter- Logothetis,a medical oncologist, Oncologists are learning to use these nationally recognized cardiologist, and Andrew von Eschenbach, a revol ution a r y therapies wis e ly, gu i d ed has spent his career developing urologist who has become director by biochemical markers that help better treatments for and helping of the National Cancer Institute, at monitor their effectiveness. patients survive heart disease. M. D. Anderson Cancer Center. The markers are “predictive of One night in 2001,he woke with an “We’l l get you fixed up,” Dr . Logot h e tis relapse, and can guide the selection unusual pain in his stomach. Lying said. He prescribed an innovative of fu tur e therap y,” sa ys Dr. Logot h e tis . in bed, he examined his abdomen and aggressive regimen of hormones “When we needed funding to initi- and was stun n e d to find an abno rma l and chemotherapy intended to treat ate this research, only the PCF was growth.Days later, an MRI revealed advanced prostate cancer. After just willing to step forward.” metastatic prostate cancer. His prog- one day, Dr.Casscells felt better. nosis: 18 months to live. He was 48, Since completing this combination “When the Prostate Cancer at the peak of a successful medical of chemotherapy and hormones Foundation funded the develop- career, a husband and the father of two years ago, Dr.Casscells’ disease ment of this treatment program, three young children.“I wanted to remains in remission. Today, he chemotherapy for prostate cancer scream or cry, but I didn’t have foresees a longer future and hopes was regarded as a poison unfit for time,” Dr.Casscells remembers.“I to see his children graduate from humankind,” says Dr. Logothetis. envisioned writing letters to my high school and reach other mile- children and making a videotape As recently as three years ago, Dr. stones. He hasn’t sat down yet to for them to remember me. It was Casscells’ only option would have write anything to them.“I’ve been overwhelming.” been single therapy with hormones given my life back,” he says.“I don’t and the prognosis would have been know how the story turns out.”

He was 48,at the peak of a successful •Prostate cancer is the most com- medical career, a husband and the father mon non-skin cancer in America, of three young children.“I envisioned striking 220,000 men in 2003. writing letters to my children and making a videotape for them to remember me. • Prostate cancer attacks aggressively It was overwhelming.” beginning at age 50.

•The number of new cases per year is projected to increase by 50% to 300,000 by 2015.

10 “I wanted to scream or cry, but I didn’t have time.” Funding Research

The PCF Funds High- •Funded the development of vaccines Potential Research that harness the body’s immune sys t em to kill pros t a t e cancer cell s ;a n d Just as venture capital firms advance technology by funding promising •Funded gene therapy approaches commercial strategies and products, to selectively eliminate prostate the Prostate Cancer Foundation cancer cells. foll o ws a similar model by sup portin g PCF grant funding has led directly The PCF has funded more than innovative,early-stage research to many advan c es in comp rehen d i n g projects that offer the greatest hope. 1,100 crucial research projects the underlying mechanisms of in 100 research centers around These high- i m p a ct res e a r ch proje cts , prostate cancer — advances that the world. many of which would not have have or will lead to better treat- been funded without our support, ments of prostate cancer: include clinical research to evaluate • Identification of the genetic changes new drugs,innovative treatment that might cause cells in the prostate strategies for prostate cancer, and to become cancerous; basic science research to understand the biology of prostate cancer. As • Stopping the production or func- part of its efforts to move drugs into tion of growth factors that cancer the clinic quickly, the PCF has: cells need to continue growing;

•Funded the discovery and/or early •Interfering with the development of clinical develo pme nt of PSMA mono - blood vessels that feed nutrients to clonal antibodies, Velcade, Zometa, cancer cells; Atrasentan,and Omnitarg; • Determination of the structure of the androgen receptor, the molecule that drives the growth of prostate cells,and the discovery of ways to inhibit it;

All 30 Major League Baseball teams provide support for the Prostate Cancer Foundation CaP CURE Home Run Challenge in many Alaska Senator Ted Stevens,a cancer ways.Clubs host pre-game ceremonies, run survivor and chairman of the U.S. Sen a t e pub lic servic e announ c em en t s ,d o n a te tic kets , Appropria t ions Com m i t te e , has bee n one of place blue ribbons on the field and support the earliest sup por ters of the PCF and its the player representatives. Owners, coaches, mission to find better treatments and a executives,umpires, trainers, groundskeepers, cure for prostate cancer. Senator Stevens and front office staff are behind the cause by has been one of the strongest congressional ho s t ing spec ial events end o r sing and prom o tin g advocates for increased cancer funding. the Home Run Challenge.

12 • Identification of prostate cell surface and scientists who are conducting markers that can be targeted to prostate cancer research. In order destroy cancerous cells; and to attract new talent, nearly half of these PCF-funded awards are earned • Development of analytical methods by qualified researchers who have that identify the proteins in blood never before received PCF funds. or the prostate that correlate to treatment effect or behavior of the cancer cell — also known as Leaps of Faith Lead to The PCF cuts through the red Meaningful Results proteomic pattern recognition. tape of research funding. PCF The impact of PCF-funded grant applicants are limited to Competitive Awards programs is realized when they five-page submissions and get a demonstrate great promise and The PCF originated a “fast-track” response within 60 days…with receive funding from bio t echn o l o gy grant-application process so funds delivered in 90 days. and pha rm a ceutical companies researchers could devote their time or from government research to advancing science rather than ag enc i e s . Examples of PCF suc ces s pleading for funds and completing stories include: seemingly endless forms. The time from submission of a request to Velcade Chemist Julian Adams had money-in-hand was reduced to 90 lost internal support at his company days. The reporting of results was for ongoing research on a com- reduced to a six-month progress pound named PS-341 (Velcade) report letter and a presentation at and the project was about to be the annual PCF Scientific Retreat. terminated. He persuaded the PCF to fund a Phase I clinical trial of PCF competitive research awards Velcade. The results of this study have resulted in a dramatic increase were encouraging.As a result, in the number of talented physicians Millennium Pharmaceuticals, a

Nobel laureates in medicine and science debated our biological and scientific future at the 2003 Milken Institute Global Con f erence . From left: Sydn e y Brenn e r, who Bob Dole, former Senate Majority Leader received his Nobel Prize for his discoveries and presidential candidate, told attendees concerning genetic regulation of organ at the 2002 PCF Scien t ific Retreat about his Mike Milken and Baseball Hall of Fame development and programmed cell death; experience as a prostate cancer survivor. manager Tommy Lasorda look on as News Steven Chu, who received his Nobel Prize Corp. chairman Rupert Murdoch,a prostate for the development of methods to cool and cancer survivor, leads a “wave” at Dodger trap atoms with laser light; Mike Milken, Stadium to celebrate another home run that chairman and founder of the PCF and the raised money for prostate cancer research Milken Institute; and Joshua Lederberg, during the Prostate Cancer Foundation who received his Nobel Prize for discoveries CaP CURE Home Run Challenge. concerning genetic recombination. (Photo courtesy of the Los Angeles Times)

13 Funding Research

major biotech firm, acquired the known as Aredia (pamidronate) company that owned Velcade and for the prevention of bone loss invested millions of dollars to in patients undergoing androgen continue development of the drug. deprivation therapy (ADT). In 2003, the FDA approved Velcade An estimated one million men for the treatment of multiple diagnosed with prostate cancer are myeloma — a cancer of the blood. undergoing ADT with loss of bone density (osteoporosis) as a major There is significant interest in com- PCF-funded research results side effect. The results of this study bining Velcade with chemotherapy in effective treatments to were published in the New England for advanced prostate cancer and patients living with advanced Journal of Medicine in September st udies of this trea tm e nt combi n a ti o n 2001 and showed that Aredia mini- prostate cancer. are currently in progress. Further mizes bone loss and associated studies in advanced prostate cancer skeletal-related events in men and other solid tumors continue. undergoing ADT. Zometa The PCF funded medical Based on these encouraging results, oncologist Matthew Smith, M.D., Novartis,the seventh largest phar- Ph.D., of Massachusetts General maceutical company in the world Hospital to conduct a series of and the manufacturer of Aredia, clinical studies at Harvard Medical committed significant resources to School on the use of bisphospho- the development of a more potent nates in the treatment of advanced bisphosphonate known as Zometa prostate cancer. The first clinical (zolendronate) to prevent bone loss trial condu c ted by Dr. Smith focu s e d and skeletal-related events in men on the use of a bisphosphonate with pros t a t e cancer underg oing AD T .

Stewart Resnick and his wife, Lynda, a PCF board member, have long been major supporters of medical research and other charities.They joined “Magicians of the Home Run Challenge Goodwill Ambassador Century” Siegfried and Roy at a 2002 event and Baseball Hall of Fame manager, Tommy that raised several million dollars for PCF- Lasorda,stands between New York Yankees funded research. Leroy Hood,M.D., Ph.D., president,director manager Joe Torre (left),a prostate cancer and professor at the Institute for Systems survivor and New York Yankees bench coach Biology, was the architect of the PCF Gene Don Zimmer in Joe Torre’s office before a and Family Studies Consortium, which Prostate Cancer Foundation CaP CURE has created the largest repository of genetic Home Run Challenge game. samples from families with multiple indi vid- uals affected by prostate cancer. The goal of the consortium is to identify genes that cause prostate cancer.

14 In 2001, Novartis gained FDA to the ongoing development of approval for Zometa for the treat- Atrasentan to treat prostate cancer. ment of prostate cancer and other The drug is now in Phase III clinical solid tumors in bone. trials to determine whet h e r Atras en t a n can inhibit the growth of prostate Atrasentan In the early 1990s, a cancer cells in bone, relieve pain, drug called Atrasentan (formerly and improve quality of life for those designated ABT-627) was being patients living with prostate cancer. developed by Abbott Laboratories, The PCF: one of the largest pharmaceutical PCF participation was crucial to The We cut red tape. companies in the world, to treat Johns Hopkins investigators because We get results. cardiovascular disease. The drug funding for these types of “out-of- blocks the activity of a molecule the-box”studies is nearly impossible We provide hope. called endothelin that closes blood to obtain. Without PCF funding vessels.A team of scientists at The of this high-potential research, Johns Hopkins University discov- Atrasentan may have never been ered that endothelin also caused developed to treat prostate cancer. prostate cancer cells to grow. They Omnitarg Dr. David Agus, a medical applied to the PCF for funds to test oncologist at Cedars-Sinai Health Atrasentan.PCF-funded research Science Center in Los Angeles, was demonstrated that Atrasentan formerly studying leukemia and slowed prostate cancer growth in lymphoma at Memorial Sloan- test tubes and in animal models. Kettering Cancer Center (MSKCC) Based on these results, Abbott in New York.Scientists at MSKCC Laboratories has committed recru i t ed Dr. Agus to begin laborat ory hundreds of millions of dollars

Celestia Higano, a medical oncologist at the University of Washington,describes results from a recent clinical trial of a new drug for advanced prostate cancer to PCF chairman Gary Becker, Nobel laureate in economics, and founder Mike Milken at the 2001 PCF spoke at the 2002 PCF Scientific Retreat. Scientific Retreat at Lake Tahoe. Becker, considered one of the world’s leading economists,has helped the PCF direct strate- gies in research funding. Recognized for his expertise in human capital,economics of the family, and economic analysis of crime, discrimination and population, Becker is a prostate cancer survivor.

15 Funding Research

studies to characterize new drug model case for the positive influence candidates for prostate cancer. One of the PCF on pharmaceutical su ch dru g, produ ced by bi o tech- companies to invest in prostate n o l ogy company Genentech and cancer drug development. known as Omnitarg (formerly 2C4), PSMA Monoclonal Antibodies was studied by Dr.Agus and was Frequently, drugs developed by determined to be a potential treat- PCF-funded investigators produce ment for human prostate cancer. Drugs developed by PCF-funded treatments for many types of cancer. investigators produce treatments Upon relocation to the Warschaw PCF-funded research conducted Prostate Cancer Center at Cedars- by Dr. Neil Bander at Cornell for all types of cancer. Sinai, a member of the PCF Therapy University Medical School in New Consortium,Dr.Agus was funded York focuses on the use of a mono- to furth e r develo p Omnitarg. Arme d clonal antibody against Prostate- with these preclinical results in Specific Membrane Antigen prostate cancer, the PCF persuaded (PSMA), a molecule found on Gen en t ech, a bio t echn o l o gy comp a n y, the surface of prostate cancer cells. to conduct further development of Monoclonal antibodies are proteins this drug candidate with pros t a t e engineered in the laboratory to bind ca n c er as the lead indication . specifically and potently to a single molecule. Intravenous injections This represents great progress of monoclonal antibodies against because most drugs are initially PSMA have been demonstrated to tested in other cancers because of concentrate at sites of prostate the special challenges in evaluating cancer. This shows that they can eff i c a cy in pros t a t e cancer. The be used to deliver lethal doses of develo pmen t of Omnitarg is a

Intel chairman and PCF board memb er Andrew Grove has helped accelerate the pac e of me dical rese a r ch by sharing bus i n e s s Dr. Jonathan Simons, a medical oncologist principles that have led to success in the and Cancer Center director at Emory high-tech industry. Dr. Grove is also a University, is a PCF-funded physician/ prostate cancer survivor. scien ti s t . Dr. Simons has made signi f i c a n t contributions in the area of prostate cancer vaccines.

16 radiation or toxins directly to companies, Progenics and Medarex, prostate cancer, eradicating or are developing their own PSMA reducing the tumor. monoclonal antibodies specifically for the treatment of prostate cancer. Subsequent work showed that this approach had even greater potential. These novel therapies illustrate PSMA molecules, which had been the progress being made. The hard thought to exist only in prostate work of PCF-supported researchers cancer cells, were discovered on the over the past 10 years is producing The PCF has significantly acceler- surface of cells lining new blood therapies that are entering the ated the pace of discovery and vessels that feed many tumors in clinical-trial stage at an increased development of the most promising addition to prostate cancer. This rate. This provides hope for men suggested a potentially broad thera- already living with prostate cancer, prostate cancer treatments. peutic activity of PSMA monoclonal as well as the approxi m a t ely 220,000 antibodies for breast, lung, and men who will be diagnosed with colon cancers, in addition to prostate cancer in 2003. prostate cancer.

Realizing the potential of this new treatment, biotechnology company Millennium Pharmaceuticals is currently funding the clinical devel- opment of this PSMA monoclonal an ti b ody not onl y for pros t a t e cancer, but potentially for other cancers as well. At least two other pha rm a ceutic a l

Christopher Logothetis,M.D., chairman of genitourinary medical oncology at the University of Texas M. D. Anderson Cancer Center, is at the forefront of clinical research In 2001,the PCF sponsored a run/walk to on prostate cancer. Dr. Logothetis was a raise prostate cancer awareness. More than founding member of the Prostate Cancer 5,000 men, women,and children assembled Foundation Therapy Consortium. At the at the Los Angeles Staples Center for the 2002 PCF Scientific Retreat in Washington, Champions Challenge for a Cure. D.C.,he presented the results of his research on specific gene-therapy approaches to prostate cancer.

17 Funding Research

Increased Government Fun d i n g Specialized Program of Research Excellence The Prostate Cancer Foundation has been a strong and successful The Specialized Program of advoca t e for increa s e d governm en t Research Excellence (SPORE) funding for pro s t a te cancer encourages translational science research. Since 1993, the PCF has that spans the gap between basic raised awareness that has helped research and clinical applications. Since 1993, the PCF has raised to in c r ease annual governm e nt The first two prostate cancer awareness that has helped to funding earmarked for prostate SPOREs were funded in 1992 cancer from $25 million to more and increased to three in 1995. increase annual government than $500 million. The increased Today, there are 11 prostate cancer funding earmarked for prostate funding of prostate cancer research, SPOREs with a total annual budget cancer from $25 million to and cancer research in general, of approximately $27 million. more than $500 million — has resulted in a major increase in treatment programs. a 20-fold increase. The Department of Defense Prostate Cancer National Cancer Institute Research Program

The PCF encouraged the National In 1996, the PCF worked closely Cancer Institute to expand its with the National Prostate Cancer Specialized Program of Research Coalition and successfully urged Excellence program that helps to Congress to provide Department accelerate the pace of development of Defense funds specifically for of some of the most promising prostate cancer research under a prostate cancer drugs. new mandate, the Prostate Cancer

International financier Thomas H. Lee (left) attended the PCF Shadow Creek Invitational along with Jerry West (center), one of the 50 greatest players in NBA PCF boar d memb er David Koc h and his wife , history, and Dr. Howard Scher, a PCF- Ju l i a ,h ave long bee n gene rous sup por ters of funded investigator at Memorial Sloan- medical research and other charities.This Kettering Cancer Center in New York,an The PCF supports physician/scientists at the year, the PCF launched the David H. Koch internationally recognized investigator in forefront of translational research.These Awards.Mr.Koch’s extraordinary generosity the field of genitourinary cancers. scientists advance drugs from the laboratory enabled the PCF to provide more than bench to the patient’s bedside. Translational $3 million to fund major research programs. research scientists are one of the most impor- tant catalysts for the development of new therapies for advanced prostate cancer.

18 Research Program (PCRP). The PCRP’s mission promotes innovative, multi-institutional, multidisciplinary research aimed at eradicating prostate cancer. To date,the PCRP has provided $395 million and has funded 797 peer-reviewed projects in response to congressional appropriations. As a result of the Prostate Cancer The PCRP has become the second Foundation’s advocacy, California la r g est funder of prostate cancer now requires that health insur- research in the United States. ance companies and Medi-Cal This increase in federal support pay for routine treatment costs has created a large and stable source incurred by cancer patients in of funding needed to continue the clinical trials. development of new drugs discov- ered by PCF-funded research and has attracted a critical mass of scientists contributing to the prostate cancer field.

Safeway joined the PCF in the fight against prostate cancer with two longbed trucks that travel throughout Northern and Southern The Donald J. Trump Pro/Am Tennis California. As part of a fund-raising effort Invitational at the Mar-a-Lago Club in each year during the month of June,Safeway Palm Bea c h has rai s ed more than $5 milli o n and Vons customers made donations to the for prostate cancer research since the PCF’s cancer-fighting efforts at checkout program began in 1998. coun t ers .S a feway empl o yees also par tici pa t ed in a corporate donation drive.

19 Patient Profile

William Clapp learned,” he says, “the more afraid here is the whole approach of Diagnosed with prostate I was of dying.” Mr.Clapp elected trying drugs preoperatively, which cancer at age 63. to be treated by Dr. Philip Kantoff, is very labor-i n t ens i ve and exp ens i ve a Pros t a t e Can c er Fou n d a ti o n- and would not have been possible When he changed doctors at age supported oncologist who heads without the PCF’s vision and 63, William Clapp received his first the Lank Center for Genitourinary funding.” Without it,Mr.Clapp prostate specific antigen (PSA) test. Oncology of the Dana-Farber might have been written off as a The results showed that he probably Can c er Ins ti t ute at Har var d Medi c a l ho peless case. Ins te ad , he has done had metastatic prostate cancer. School. Mr.Clapp participated in extraordinarily well. This simple blood test detects a PCF-funded study that uses the amount of prostate specific Mr.Clapp continued to work chemotherapy before surgery. antigens in the blood. The higher during chemotherapy and missed the reading, the greater the likeli- Men such as William Clapp, with only a month of work after surgery. hood of prostate cancer. very high PSA levels, are typically Then, in May 2002,at age 65,he poor candidates for surgery because retired. Now he spends his days Medical authorities recommend their disease often has spread to working out at a YMCA, taking that all men have annual PSA tests other organs. “They receive hor- culinary arts classes, and playing beginning at age 50 (or age 40 for mones plus radiation, and then you with his young grandsons. His PSA African American men or those just cross your fingers,” Dr.Kantoff has remained at zero for the past with a family history of prostate says. Because Mr.Clapp’s prostate two years. And he can look forward cancer since they are at higher risk). cancer appeared to be confined, once again. Nonetheless, Mr.Clapp’s prior surgery was a possibility, especially physician had neglected to conduct His whole perspective on life has with the use of chemotherapy a PSA test. changed.“I’m more calm now, before surgery. because there are more important Mr.Clapp’s own test results Although the chemotherapy made things in life.I want to live longer prompted him to research the the difference between success and than my grandfather, who died at disease thoroughly. “The more I failure, Dr.Kantoff says, “The story 93.I think I can do it. I feel like I’m born again.”

Family histories and genes may hold the • Black men have the highest key to solving part of the prostate cancer incidence of prostate cancer in puzzle.The PCF Gene and Family Studies the world. Consortium created the largest repository of genetic samples from families with multiple • Compared to Caucasian men, they individuals affected by prostate cancer. The are 1.5 times more likely to get consortium partnered with academic experts prostate cancer and 2.3 times more to discover cancer-related genes and targets that can lead to new medications. likely to die from prostate cancer.

•Prostate cancer has the strongest familial link of all major cancers.

20 “The more I learned, the more afraid I was of dying.” Collaboration

The Prostate Cancer Foundation The Prostate Cancer Foundation has created and supported a series Research Therapy Consortium of networks and consortia among in 2002: academic research scientists, • M. D. Anderson Cancer Center bio t echn o l o gy and pha rm a ceutic a l comp a n i e s , governm e nt res e a r che rs, •The Johns Hopkins University and grassroots organizations to maximize collaboration and •University of California, The PCF has assembled a idea exchange. All PCF-funded San Francisco team of medical oncologists researchers are required to share • Memorial Sloan-Kettering at eight leading U.S. cancer their findings with colleagues Cancer Center around the globe and participate centers that specialize in actively with other research leaders. • Cedars-Sinai Prostate Cancer Center prostate cancer research. •University of Wisconsin Therapy Consortium •University of Michigan The PCF has assembled a team of medical oncologists at eight leading • Dana-Farber Cancer Institute, U.S. cancer centers that specialize Harvard Medical School in prostate cancer research. The Members test each other’s ideas; mem b ers of this The rap y Cons o rtium coll a b orat e in des i gn i n g , condu c tin g , meet regularly to address major and evaluating clinical trials, many is s ues that impede progress in cli n i c a l of which were funded by the PCF; development of new treatments. and develop new drugs and treat- ments. Major contributions and activities of the group include:

A routine physical in 1997 brought the news to professional golfer Jim Colbert that he had prostate cancer. Now he’s joining golf legend and fellow prostate cancer survivor Arnold Donald S. Coffey, Ph.D. (left), considered the years of progress with PCF medical director, Palmer in a partnership between the “fa t h e r of pros t a t e cancer rese a r ch, ” is profes so r Stuart Holden,M.D. (right),and Leslie D. Champions Tour and the PCF to raise of urology, oncology and pharmacology and Michelson,PCF vice chairman and CE O , funds for prostate cancer research. molecular sciences at The Johns Hopkins at the PCF Ninth annual Scien t ific Retrea t . Uni versi t y. Dr. Coff ey discu s s ed the PCF’s 10

22 • Establishing taxane-based bio t ech and pha rm a ceutical comp a n y chem o t h e rap y as a trea tm e nt optio n executives. For three intensive days, for advanced prostate cancer; these leaders address scientific advances, present ongoing research, • Acting as a planning group to initia t e deba t e topical issues rela t ed to pros t a t e new academic and industrial trials cancer, and examine better ways to for prostate cancer treatments; fund research and produce results. • Screening new drugs for inclusion The 2002 Prostate Cancer The PCF selects and provides in trials; Foundation Scientific Retreat was funding for high-impact he ld in Was h i n g t on, D.C . to highl i gh t •Participating in clinical-trial projects capable of producing standardization programs; and the importa n c e of the governm en t ’s role in our efforts. Dr.Andrew von cutting-edge results by some • Working together to select a clinical Eschenbach, newly appointed by of the world’s most forward- research informatics system to link President Bush as director of the thinking scientists. the participating centers. Na ti onal Ca n cer In s ti tute and a pro s t a te cancer su rvivor, s po ke eloquently of the Prostate Cancer Scientific Retreat Fou n d a ti o n’s eff ectiveness in “getti n g The Prostate Cancer Foundation done the things that need to be done . ” Scientific Retreat has become one of the most prominent annual me dical events in the nati on ,d rawing hundreds of pioneering scientists and physicians, government leaders, prostate cancer advocates,and

Several hundred thousand people from more than 600 cancer groups across America met on the Washington Mall in 1998 for THE MARCH: Coming Together to Cure Cancer. Businessman Carl Lindner (left), owner THE MARCH helped raise awareness of of the Cincinnati Reds and Honorary PCF cancer issues on Capitol Hill and preceded board member, has been an avid and a major increase in government funding of generous supporter of the Prostate Cancer prostate cancer research. Foun d a t ion CaP CURE Home Run Challen ge .

23 Collaboration

The Prostate Cancer This program is the PCF’s first step Foundation in Israel in linking scientific leaders from around the world in an intensified The Prostate Cancer Foundation effort to find better treatments and began funding research programs a cure for prostate cancer. in Israel three years ago. Since inception, nearly $4.7 million has been provided to 59 programs. Partnering with Industry The Prostate Cancer Foundation The PCF has achieved many of the Moving a treatment from lab to objectives in Israel that have been and the investigators it funds market can take as long as 12 years. benchmarks of PCF activities in work closely with many pharma- For the Prostate Cancer Foundation, the U.S. Specifically, the PCF has that is simply too slow. That is ceutical and biotech companies recruited the best and brightest to why the PCF works closely with including: Abbott Laboratories, the field, initiated venture programs, biotechnology and pharmaceutical Bayer, Cell Genesys, Genentech, and faci l i t a t ed significant netw orki n g companies to get res e a r ch innovati on s among scientists from many Gl a x o S m i t h K line, Medarex, Merck, to patients faster. Israeli institutions. In addition, Millennium Pharmaceuticals, the PCF initiated a Centers of PCF funding has allo wed inves ti ga t ors Novartis, and Pfizer. Excellence program that requires to accelerate the pace of develop- multiple centers to join in a single me nt of the most promising pros t a t e proposal with significant impact on cancer treatments by: the science of prostate cancer. In 2002, the PCF funded a Centers of •Funding the underlying science that Excellence award that joined the led to the treatment being studied; Technion Institute,the Weizmann •Funding early clinical trials; and Institute,and Hadassah University Hospital. This multidisciplinary • Encouraging and assisting program has the pot ent ial to gene rat e the company. new drug ta r g ets for the trea tm e nt of recu r rent prostate cancer.

PCF chairman Mike Milken (second from right) stands with some of the PCF’s biggest Home Run Challenge supporters. From left: Former A’s and Twins catcher and founding Steve Burd (left), Safeway president Home Run Challenge co-chair Terry and CEO, introduces Prostate Cancer Stein ba c h and Bal ti m o r e Orio les minorit y Foundation chairman Mike Milken at owners Bill Beatson Jr. and Steve Geppi. Cincinnati Reds outfielder Ken Griffey Jr. Safeway’s kickoff to its month-long is a Prostate Cancer Foundation CaP CURE campaign to raise money for prostate Home Run Challenge featured star represen- cancer research. tative. With such awesome power supporting the 2003 Home Run Challen ge , it was anoth e r groundbreaking year for the PCF in its mission to find better treatments and a cure for prostate cancer.

24 Raising Money and Awareness

The Prostate Cancer Foundation tic kets , place blue ribbons on conducts many programs aimed at the field,and support the player raising not only research fu n d i n g repres en t a t ives . In ad d i ti on ,a ll Maj o r but also public awa r eness of the League managers, such as Joe Torre significance of prostate cancer. of the New York Yankees and Dusty Baker of the Chicago Cubs, both prostate cancer survivors, also par- The Prostate Cancer tic i p a te . Owne rs, execu tives , coache s , Foundation CaP CURE Since 1996, the PCF has part- umpires, trainers, groundskeepers, Home Run Challenge nered with Major League Baseball and front office staff are behind and the Major League Baseball Since 1996, the PCF has partnered the cause by hosting special events end orsing and promo t ing the Home Players Association to raise more with Major League Baseball and the Major League Baseball Players Run Challenge. than $18 million for prostate As s oc i a ti on to raise more than cancer research. $18 mill i on for pro s t a te cancer Safeway and the Prostate re s e a rch . E ach Ju n e , fans pled ge Cancer Foundation anywhere from 25 cents to $10,000 for every home run hit in 60 sele cted Safeway, one of the largest food games the week before Father’s Day. reta i l e rs in North Ame ri c a ,p a rtne red All 30 Major League Baseball teams with the PCF for a third year in a provide support for the Home row to raise money and awareness. Run Challenge in many ways. Clubs Steve Burd, Safeway’s president and host pregame ceremonies, run pub- chi e f execu tive off i c er, le d a comp a ny - lic se rvic e announcemen t s , dona t e wide campaign that included

Lowell Milken (left) with PCF medical director Stuart Holden,M.D. (far right) at the 2001 PCF Scientific Retreat held at Lake Tahoe, Nevada. Lowell Milken, co- f oun d e r of the Mil k en Fam i l y Foun d a ti o n , has been one of the top supporters of the PCF since its inception in 1993.

25 Raising Money and Awareness

point-of-purchase promotions at Arnie’s Army more than 15,000 checkout stands in all 1,600 Saf ewa y stores in the U.S . Named for honorary chair Arnold Employees also participated in Palmer, this program involves in t ernal fund-raising drives to boos t pa r tic i p a t ing gol f cou r ses spons o rin g proceeds. In 2003, the campaign one-day, closest-to-the-pin contests raised more than $2.5 million for on a pres el e cted par-3 hole. Ban n e rs, prostate cancer research. tee markers, pin flags, and other The Prostate Cancer Foundation collateral materials carry the has supported research on the program logo and all golfers are Champions Tour for the Cure encouraged to join Arnie’s Army effects of nutrition on prostate to raise funds and generate public Led by golf legends and prostate cancer and other serious diseases. awareness of prostate cancer. cancer survivors Arnold Palmer, Jim Col b ert, Bobby Wal z el, and Ray Floyd, In 2002, the Prostate Cancer this program focuses on fans of the Foundation began the program Champions Tour.Supporters pledge in the North Florida section of the $1 or more for each birdie made by PGA. This year, Arnie’s Army moves their favorite player(s) during the across the nation with the goal of se a s on . Every bir die made betw een the enlisting hundreds of golf courses MasterCard Championship in late and thousands of golfers. January through the season-ending Champions Tour Championship at Gaillardia in October supports prostate cancer research.

Talk show host Larry King joined Whoopi Goldberg,mistress of ceremonies at the 1998 PCF New York Dinner. Larry has often featured PCF chairman and founder Mike Hal l of Fame hockey legend Wayne Gretz k y Milken on his television show to discuss participated at the PCF Champions prostate cancer research. Challenge for a Cure Run/Walk at the Boxing champion and Olympic gold Staples Center in Los Angeles.The annual medalist Sugar Ray Leonard joined fashion walk and interactive sports festival is a designer Pamela Dennis and other celebrities family event that increases awareness of the at the PCF Shadow Creek Invitational golf effects of prostate cancer on men and their tournament fund-raising event. families,and raises money to increase cancer research funding.

26 Nutrition trials evaluating specific nutrition and lifestyle changes in men,show Scientists now know that prostate the importance of nutrition in cancer, like all cancers,is the result preventing cancer. of damage to certain genes that regulate the growth and death of From its earliest days, the Prostate cells. This damage is caused by a Cancer Foundation has supported complex, but incompletely under- research on the effects of nutrition st ood ,i n teractio n betw een heredi t y on prostate cancer and other serious The PCF has invested more than and environment. diseases. And we have published $4 million in nutritional research the results of those studies to pro- at 13 leading research centers. Dif f erent types of sc i en t ific evid enc e vide practical guidance for patients. collectively suggest that diet and The PCF has invested more than lifestyle may account for or con- $4 milli o n in nutriti o nal res e a r ch at tribute to a significant portion of 13 leading res e a r ch cent ers includ i n g cancers, including prostate cancer. Harvard University, The Johns For example,the incidence of Hopkins Uni versi t y, MI T , Memo ria l prostate cancer in Asian men, whose Sloan-Kettering Cancer Center, diets have relatively small amounts Rockefeller University, and the of fat and large amounts of soy UC L A Cent er for Human Nutriti on . protein, is much less than that in American men. Yet, when Japanese Researchers have investigated the men migrate to the United States value of a low-fat, high-fiber diet and adopt American eating habits, rich in fruits, vegetables, and grains, their rate of prostate cancer rises to as well as foods believed to contain American levels within a generation. beneficial properties, including so y In addition, basic science research prot ein , cook ed toma t o product s , on animals and cells, and clinical and cruciferous vegetables such as broccoli.

Every other year, the PCF hosts a fund- Producer/songwriter David Foster (right), a raising event at the Waldorf-Astoria Hotel 14 - t ime Gram m y Awar d win n e r, and reno wne d in New York to raise money for p rostate Australian golf legend Greg Norman provide cancer research. Past honorees Steve and some ent erta i n m e nt at the PCF Sha d o w Cree k Elaine Wynn (center) receive the PCF eagle Invitational golf tournament to raise money statuette presented by Honorary PCFboard for prostate cancer research. member Robert Wagner and his wife , Named for honorary chair Arnold Palmer, Jil l St. Joh n ,( l eft) and PCF cha i rm a n and a prostate cancer survivor, the Arnie’s Army founder Mike Milken (right). program involves participating golf courses spo n so r ing one-day, clo se s t - t o-the-pin con te s t s on a preselected par-3 hole. Golfers are encouraged to join Arnie’s Army to raise funds and generate public awareness of prostate cancer.

27 Raising Money and Awareness

Although the evidence provides few To help men understand these and absolute truths, studies show that: other findings and adopt healthier lifestyles,the Prostate Cancer • Men who eat more cooked tomato Foundation has published two products had fewer cases of prostate cookbooks, The Taste for Living cancer. Lycopene, a powerful antiox- Cookbook, and The Taste for Living idant, is released and becomes more WORLD Cookbook.Both contain bioavailable when tomatoes are great-tasting, thoroughly tested, heated. It may inhibit processes in easy-to-prepare recipes. We have the body that lead to cancer. also published the fourth edition • A low-fat,high-fiber diet rich in of the monograph Nutrition and fruits, vegetables, soy, and grains Pros t a t e Cancer, whi c h des c ri b es the may halt, or even reverse,the current state of nutrition research. growth of prostate cancer. Both cookbooks and the mono- graph are available on our web site: • Men who consume large quantities www.prostatecancerfoundation.org. of red meat and dairy products may increase their risk of prostate cancer.

• Being overweight increases the risk of virtually every cancer. An American Cancer Society study showed that overweight men were 52% more likely to die from cancer than men of normal weight.

When former New York city schools official Harold Kobliner, Ph.D. was diagnosed with prostate cancer, he and his family searched Nutrition and Prostate Cancer: A for answers.The PCF’s nutrition project Monograph from the PCF Nutrition presented an alternative therapy supported Project gives prostate cancer patients nutri- by ongoing scientific research. tional approaches to fighting the disease. Men who eat more cooked tomato products had fewer cases of prostate cancer. Lycopene, a powerful antioxidant,is released and becomes more bioavailable when tomatoes are heated. It may inhibit processes in the body that lead to cancer.

28 We didn’t get to these people in time. We can and must do more. The need remains great. Your help has never been more important.

Timothy Leary 1920-1996 Telly Savales 1924-1994 Steve Ross 1927-1993 Francois Mitterand 1916-1996

Linus Pauling, Ph.D. 1901-1994 Jay Chiat 1934-2002 Bill Bixby 1934-1993 Frank Zappa 1941-1993

29 Patient Profile

Professor Gerald Haslam to receiving a vaccine or flu shot. Dr.Small’s colleague,urologist Diagnosed with prostate Compared to other treatments for Peter Carroll,agrees. “The PCF cancer at age 60. prostate cancer, immunotherapy has gave us not only the impetus, but proven to be relatively nontoxic. the guidance to become better. As When author and professor Gerald a result, we have been able to help Haslam retired after 30 years at “I’d always planned to retire at 60,” many more patients with high-risk Cal i f ornia State Uni versi t y, li f e wasn’t Professor Haslam says,“just not prostate cancer.” what he expected. Just months after under these circumstances. I was undergoing prostate surgery and alw a ys an athlete and stil l cons i d ered Today, Mr.Haslam’s PSA is down radiation treatment, the news from myself young and alive.” to an acceptable level. He continues one of his follow-up visits was his fight against prostate cancer and “The best patient care always comes devastating: his PSA level was on expects to enter another clinical trial from integrating the most innova- the rise. His physician feared that involving the hereditary factors of tive and novel therapeutics with a his cancer had return e d and referred the disease. Because his family has vigorous research program,” says Dr. him to the University of California, a history of prostate cancer, he and Small. “Without the PCF’s financial San Francisco (UCSF), a leading his three sons are also participating support of UCSF’s immunotherapy cancer center and one of eight in a PCF-funded study of familial research, Mr.Haslam’s treatment members of the Prostate Cancer predisposition for prostate cancer. options would have been limited. Foundation Therapy Consortium. Our participation in the Prostate “Whe n I do die, my death wil l have Dr. Eric Small, an oncologist, Cancer Foundation Therapy been of value in the long-term enrolled Mr.Haslam in a PCF- Consortium has helped transform struggle. And if something I experi- funded clinical trial of an innovative us into a top-tier cancer center. ence helps my sons down the road, form of immunotherapy that stimu- We strengthened our research that’s a wonderful gift. Hope in any lates the body’s immune system infrastructure to complement the form is priceless,” says Mr.Haslam. to eradicate prostate cancer cells. expertise we already had.” Immunotherapy is similar in theory

Gerald Haslam continues his fight against • One in six men will get prostate prostate cancer and expects to enter another cancer in their lifetimes. clinical trial involving the hereditary factors of the disease. Because his family has a his- • Every 2 1/2 minutes a man is tory of prostate cancer, he and his three sons diagnosed with prostate cancer. are also participating in a PCF-funded study of familial predisposition for prostate cancer. • Ever 18 minutes, a man dies from prostate cancer in the United States.

30 “I ’ d alwa ys planned to retir e at 60, just not under these circu m s t a n ce s . ” Research Awards

Albert Einstein College of Medicine California Institute of Technology $75,000 $450,000 Nicole B. Schreiber-Agus,Ph.D. Raymond J.Deshaies,Ph.D. Huatao Guo, Ph.D. Assaf Harofe Medical Center (Israel) Alexander J.Varshavsky, Ph.D. $150,000 Amnon Zisman,M.D. California Pacific Medical Center $100,000 Bar-Ilan University (Israel) Robert J. Debs,M.D. $225,000 Shlomo Grossman,Ph.D. Cancer Institute of New Jersey Uri Nir, Ph.D. $75,000 2002 David H. Koch Awa r d s Robert S. DiPaola,M.D. Baylor University This year the Prostate Cancer $3,200,000 Cantonal Hospital St.Gall Foundation launched the David Jacques Banchereau,Ph.D. (Switzerland) H. Koch Awards. Mr. Koch’s $75,000 extraordinary generosity enabled Baylor College of Medicine Marcus Groettrup, Ph.D. the PCF to provide more than Norman M. Greenberg, Ph.D. Dov Kadmon,M.D. $3 million to fund major research Case Western Reserve University Paula Kaplan-Lefko, Ph.D. programs at: $275,000 Michael Kattan,Ph.D. Sanford Markowitz,M.D.,Ph.D. •The Johns Hopkins University Dolores J. Lamb, Ph.D. Bingcheng Wang, Ph.D. Bert W. O’Malley, M.D. • M. D. Anderson Cancer Center David R. Rowley, Ph.D. Cedars-Sinai Medical Center Peter T. Scardino, M.D. $1,995,000 • Memorial Sloan-Kettering Timothy C. Thompson,Ph.D. David B.Agus,M.D. Cancer Center Ming-Jer Tsai,Ph.D. H.Phillip Koeffler, M.D. Nancy L. Weigel,Ph.D. Isett Laux,Ph.D.

Ben-Gurion University Cleveland Clinic Foundation of the Negev (Israel) $150,000 $375,000 Katerina Gurova,Ph.D. Ron N. Apte,Ph.D. Edward Plow, Ph.D. Joseph Levy, Ph.D. Angel Porgador, Ph.D. Cold Spring Harbor Laboratory Shraga Segal,Ph.D. $100,000 Robert Lucito, Ph.D. Brandeis University $250,000 Columbia University Lizbeth Hedstrom,Ph.D. $2,129,500 Gregory A. Petsko, Ph.D. Allen Pavilion Presbyterian Hospital Burnham Institute Carl A. Olsson,M.D. $1,686,000 Atchley Pavilion Wadih Arap, M.D.,Ph.D. Ralph Buttyan,Ph.D. Nuria E. Assa-Munt,Ph.D. College of Physicians and Surgeons Kathryn R.Ely, Ph.D. Paul B. Fisher, Ph.D. John C. Reed,M.D.,Ph.D. Aaron E. Katz,M.D. Erkki I Ruoslahti,M.D.,Ph.D. Nickolas Papadopoulos,Ph.D.

Columbia Presbyterian Medical Center Daniel Petrylak,M.D.

32 Cornell University Hadassah University (Israel) Harvard School of Public Health $4,100,000 $425,000 June M. Chan,Sc.D. Beatrice S. Knudsen,M.D.,Ph.D Rachel Bar-Shavit,Ph.D. Edward Giovannucci,M.D. David M. Nanus,M.D. Eithan Galun,M.D.,Ph.D. Laurie H.Glimcher, M.D. Amnon Peled,Ph.D. Dimitrios Trichopoulos,M.D. New York Presbyterian Hospital Eli Pikarsky, M.D.,Ph.D. Neil H. Bander, M.D. Israel Vlodavsky, Ph.D. Massachusetts General Hospital Joel Finkelstein,M.D. Dartmouth-Hitchcock Harvard University Robert L. Martuza,M.D. Medical Center $10,625,000 Matthew R. Smith,M.D.,Ph.D. $75,000 Ching-Hsuan Tung, Ph.D. Marc S.Ernstoff,M.D. Beth Israel Deaconess Medical Center Anthony L. Zietman,M.D. Lewis C. Cantley, Ph.D. Duke University John V. Fragioni,M.D.,Ph.D. Hebrew University (Israel) $925,000 Sandra M.Gaston,Ph.D. $800,000 Eli Gilboa,Ph.D. Towia A.Libermann,Ph.D. Yinon Ben-Neriah,M.D.,Ph.D. Michael C.Pirrung, Ph.D. Massimo Loda,M.D. Howard Cedar, M.D.,Ph.D. David T. Price,M.D. Jan E.Schnitzer, M.D. Eli Keshet,Ph.D. Johannes W. Vieweg, M.D. Brigham and Women’s Hospital Alexander Levitzki,Ph.D. Eastern Virginia Medical School Anthony V. D’Amico, M.D.,Ph.D. David Naor, Ph.D. $175,000 Phillip Febbo, M.D. Indiana University George L. Wright Jr.,Ph.D. James W. Fett,Ph.D. Joshua LaBaer, M.D.,Ph.D. $200,000 Emory University Kevin R. Loughlin,M.D. Thomas A.Gardner, M.D. $250,000 Karen A. Olson,Ph.D. George W. Sledge,M.D. Wayne Harris,M.D. Jeffrey L. Sklar, M.D.,Ph.D. Institute for Systems Biology John A. Petros,M.D. Children’s Hospital $500,000 Judah Folkman,M.D. Erasmus University (Netherlands) Leroy E. Hood,M.D.,Ph.D. Michael Klagsburn,Ph.D. $250,000 Calvin J.Kuo, M.D. John Wayne Cancer Institute Jan Trapman,Ph.D. Marsha A. Moses,Ph.D. $50,000 Gert J. van Steenbrugge,Ph.D. Richard C. Mulligan,Ph.D. Frederick R. Singer, M.D. Fred C. Hutchinson Cancer Bruce R. Zetter, Ph.D. Johns Hopkins University Research Center Dana-Farber Cancer Institute $12,897,000 $2,605,000 Ranaan Berger, M.D.,Ph.D. Philip A. Beachy, Ph.D. Peter S. Nelson,M.D. Myles A. Brown,M.D. G.Steven Bova,M.D. Elaine A.Ostrander, Ph.D. Harvey Cantor, M.D. Michael A. Carducci,M.D. Janet L.Stanford,Ph.D. Diego Castrillon,M.D.,Ph.D Angelo DeMarzo, M.D.,Ph.D. Lan Bo Chen,Ph.D. Samuel R. Denmeade,M.D. Georgetown University Glenn Dranoff,M.D. Mario Eisenberger, M.D. $1,000,000 Daniel J. George,M.D. John T.Isaacs,Ph.D. William C. Hahn,M.D.,Ph.D. Lombardi Cancer Center William B.Isaacs,Ph.D. Philip W. Kantoff,M.D. Edward P. Gelmann,M.D. Hyam I. Levitsky, M.D. David M.Livingston,M.D. Robert L. Martuza,M.D. Joel B. Nelson,M.D. Massimo Loda,M.D. Renxiao Wang, Ph.D. William G. Nelson,M.D.,Ph.D. Thomas Roberts,Ph.D. Shaomeng Wang, Ph.D. Alan W. Partin,M.D.,Ph.D. William R. Sellers,M.D. Ronald Rodriguez,M.D.,Ph.D. Sabina Signoretti,M.D. Jonathan W. Simons,M.D. Bruce M.Spiegelman,Ph.D. Patrick C. Walsh,M.D. Robert H. Vonderheide,M.D., D.Phil.

33 Research Awards

Karolinska Institute (Sweden) Zvi Fuks,M.D. $75,000 Polly Gregor, Ph.D. Hans-Olov Adami,M.D.,Ph.D. Adriana Haimovitz-Friedman,Ph.D. Warren D.W.Heston,Ph.D. Klinikum de Justus-Liebig William Kevin Kelly, M.D. Universitat Giessen (Germany) Philip O. Livingston,M.D. $175,000 Paul A. Marks,M.D. Trinad Chakraborty Michael R. McDevitt,Ph.D. David Nanus,M.D. La Jolla Institute for Neal Rosen,M.D.,Ph.D. Allergy and Immunology Michael Sadelain,M.D.,Ph.D. $75,000 Peter T. Scardino, M.D. Stephen Schoenberger, Ph.D. David A.Scheinberg, M.D.,Ph.D. Howard I.Scher, M.D Long Island College Hospital George Sgouros, Ph.D. $15,000 David Shaffer, M.D.,Ph.D. Ivan Grunberger, M.D. Moshe Shike, M.D. Loyola University Medical Center Susan F.Slovin,M.D.,Ph.D. $200,000 Peter Smith-Jones,Ph.D. Eugene D. Kwon,M.D. Jedd D.Wolchok,M.D.,Ph.D.

McGill University Menzies Centre for Population $75,000 Health Research (Australia) Nahum Sonenberg, Ph.D. $50,000 David A. Mackey, M.D. Massachusetts Institute of Technology Mount Sinai School of Medicine $1,535,000 $275,000 Sandra M.Gaston,Ph.D. Michael J. Droller, M.D. Richard O.Hynes,Ph.D. Irwin H.Gelman,Ph.D. Jun Liu,Ph.D. John A. Martignetti,M.D.,Ph.D. Peter H. Seeberger, Ph.D. New York Medical College Ganesh Venkataraman,Ph.D. $150,000 Whitehead Institute for Cancer Research Institute Biomedical Research Sophie Chen,Ph.D. John M.Essigmann,Ph.D. Eric S.Lander, Ph.D. New York University Richard C. Mulligan,Ph.D. $430,000 Maarten C. Bosland, D.V.Sc.,Ph.D. Mayo Clinic and Foundation Herbert Lepor, M.D. $500,000 Ian J.Mohr, Ph.D. Lorraine A.Fitzpatrick,M.D. Samir Taneja,M.D. John C. Morris,M.D. Donald J.Tindall,Ph.D. Skirball Institute of Biomolecular Medicine Memorial Sloan-Kettering Ruben Abagyan,Ph.D. Cancer Center $14,060,000 Northwest Hospital David B.Agus,M.D. $475,000 William R. Fair, M.D., F.A.C.S. Gerald P.Murphy, M.D., D.Sc. George Farmer, Ph.D. Leonard P. Freedman,Ph.D.

34 Northwestern University St.Louis University University of Arizona $200,000 $75,000 $150,000 Wade Bushman,M.D.,Ph.D. William S.M. Wold,Ph.D. Leslie Gunatilaka,Ph.D., B.S. Zhou Wang, Ph.D. Mark W. Kunkel,Ph.D. State University of New York Ohio State University $112,500 University of Basel (Switzerland) $100,000 $75,000 Downstate Medical School M. Guill Wientjes Ph.D. Lukas Bubendorf,M.D. Jack Mydlo, M.D.

Oregon Health Sciences University Stony Brook University of Bern (Switzerland) $100,000 Victor I. Romanov, Ph.D. $100,000 Ron G. Rosenfeld,M.D. George N. Thalmann,M.D. Technion, Israel Institute of Preventive Medicine Research Technology (Israel) University of California Institute $625,000 $15,990,068 $500,000 Ami Aronheim,Ph.D. Lawrence Livermore Dean Ornish,M.D. Aaron Ciechanover, M.D., D.Sc. National Laboratory Fuad Fares, D.Sc. Christine Hartmann Siantar, Ph.D. Rabin Medical Center (Israel) Ehud Keinan,Ph.D. $50,000 Gera Neufeld,Ph.D. University of California, Berkeley Avishay Sella,M.D. Israel Vlodavsky, Ph.D. James P. Allison,Ph.D. Carolyn Bertozzi,Ph.D. Rockefeller University Tel-Aviv University (Israel) Arthur A. Hurwitz,Ph.D. $500,000 $400,000 David H. Raulet,Ph.D., B.S. Robert G. Roeder, Ph.D. Zvi Fishelson,Ph.D. Peter G.Schultz,Ph.D. Strang Cancer Research Laboratory Sara Lavi,Ph.D. David E. Wemmer, Ph.D. Ada Rephaeli,Ph.D. Martin Lipkin,M.D. University of California, Davis Ilan Tsarfaty, Ph.D. Shing-Jien Kung, Ph.D. Salk Institute for Biological Studies Sourasky Medical Center University of California, Los Angeles $760,050 Ben-Zion Katz,Ph.D. Arie S. Belldegrun,M.D. Ronald M. Evans,Ph.D. Avi Orr-Urtreger, M.D.,Ph.D. Michael F.Carey, Ph.D. Rowan T.Chlebowski,M.D.,Ph.D. San Diego Cancer Research Thomas Jefferson University Pinchas Cohen,M.D. $75,000 $125,000 Jean B. deKernion,M.D. R. Michael Williams,M.D.,Ph.D. Michael J.Mastrangelo, M.D. Purnima Dubey, Ph.D. Albert J. Wong, M.D. Scripps Research Institute Sanjiv S.Gambhir, M.D.,Ph.D. $975,000 Tulane University David Heber, M.D.,Ph.D. Ruben A. Abagyan,Ph.D. $500,000 Harvey R. Herschman,Ph.D. K.C. Nicolaou,Ph.D. Andrew V. Schally, M.D.,Ph.D. Jay R.Lieberman,M.D. Prabhakar Tripuraneni,M.D. Carl W. Miller, Ph.D. University Hospital, Ayyappan K. Rajasekaran,Ph.D. Sheba Medical Center (Israel) Nijmegen (Netherlands) Robert Reiter, M.D. $150,000 $275,000 Peter Rosen,M.D. Gideon Rechavi,M.D.,Ph.D. Marion J.G. Bussemakers,Ph.D. Marc A. Seltzer, M.D. Kathleen M. Sakamoto, M.D. Stanford University University of Alabama, Birmingham Charles L. Sawyers,M.D $1,225,000 $100,000 Marc A. Seltzer, M.D. Gerald R. Crabtree,M.D. David T.Curiel,M.D. Ke Shuai,Ph.D. David Feldman,M.D. Peter Tontonoz,M.D.,Ph.D. Calvin J.Kuo, M.D. Owen N. Witte,M.D. John E. McNeal,M.D. Hong Wu,M.D.,Ph.D. Donna M. Peehl,Ph.D. Thomas A.Stamey, M.D.

35 Research Awards

University of California,San Diego Institute of Biomedicine Dennis A. Carson,M.D. Olli A. Janne,M.D.,Ph.D. Randolph D.Christen,M.D. Lawrence S.B. Goldstein,Ph.D. University of Illinois Michael G. Rosenfeld,Ph.D. $50,000 Helen P.Tighe,Ph.D. Nissum Hay, Ph.D. Maurizio Zanetti,M.D. University of Innsbruck (Austria) University of California,San Francisco $100,000 Jeffrey Arbeit,M.D. Zoran Culig, M.D. Allan Balmain,Ph.D. Elizabeth Blackburn,Ph.D. University of Iowa Peter R. Carroll,M.D. $75,000 June Chan,Sc.D. George Weiner, M.D. Robert Fletterick,Ph.D. Mark W. Frohlich,M.D. University of Kentucky Douglas Hanahan,Ph.D. $100,000 Ronald H. Jensen,Ph.D. Vivek M. Rangnekar, Ph.D. John Kurhanewicz,Ph.D. James D.Marks,M.D.,Ph.D. University of Maryland Dean Ornish,M.D. $100,000 Mack Roach,III,M.D. Natasha Kyprianou,Ph.D. Eric J.Small,M.D. University of Massachusetts Thea Tlsty, Ph.D. $325,000 University of California,Santa Barbara Michael R. Green,M.D.,Ph.D. Dulal Panda,Ph.D. Shuk-Mei Ho, Ph.D. Mani Menon,M.D. University of Chicago $425,000 University of Michigan Douglas K. Bishop, Ph.D. $3,000,000 Carrie W. Rinker-Schaeffer, Ph.D. Arul M. Chinnaiyan,M.D.,Ph.D. Mitchell H. Sokoloff,M.D. Mark Day, Ph.D. Ben May Institute for Cancer Research Evan T. Keller, D.V.M.,Ph.D. Shutsung Liao, Ph.D. Donna Livant,Ph.D. Kenneth J. Pienta,M.D. University of Colorado Martin G. Sanda,M.D. $655,000 Shaomeng Wang, Ph.D. L. Michael Glode,M.D. William E. Huffer, M.D. University of Munich (Germany) Andrew S. Kraft,M.D. $100,000 Gary J.Miller, M.D., Ph.D. Bernd Gansbacher, M.D.

University of Connecticut University of Nebraska $100,000 $100,000 Pramod Srivastava,Ph.D. Ming-Fong Lin,Ph.D.

University of Edinburgh (Scotland) University of North Carolina, $75,000 Chapel Hill Fouad K. Habib, Ph.D. $150,000 David Ornstein,M.D. University of Helsinki (Finland) $200,000 University of Pennsylvania $400,000 Mark I. Greene, M.D.,Ph.D.

36 Wistar Institute Sunnybrook Health Science Center Veteran’s Administration George C. Prendergast,Ph.D. Shoukat Dedhar, Ph.D. $4,622 Robert S. Kerbel,Ph.D. Patricia Cornett,M.D. University of Pittsburgh $2,275,000 University of Utah, Health Volcani Center (Israel) Michael J. Becich,M.D.,Ph.D Sciences Center $180,000 Barbara A. Foster, Ph.D $100,000 Mark Pines,Ph.D. John Gilbertson,M.D. Arthur R. Brothman,Ph.D. Susan L. Greenspan,M.D. Walter Reed Army Medical Center Candace S. Johnson,Ph.D. University of Virginia $50,000 Joel B. Nelson,M.D. $3,650,000 David G. McLeod,M.D., J.D. Donald L. Trump, M.D. Leland W.K. Chung, Ph.D. Janey Whalen,Ph.D. Thomas A.Gardner, M.D. Washington University Deborah Lannigan,Ph.D. $3,339,166 University of Rochester Charles E. Myers,Jr.,M.D. William J.Catalona,M.D. $400,000 J. Thomas Parsons,Ph.D. Mark L.Day, Ph.D. Chawnshang Chang, Ph.D. Fraydoon Rastinejad,Ph.D. Helen Donis-Keller, Ph.D. Edward Messing, M.D. Mitchell Sokoloff,M.D. Steven F. Dowdy, Ph.D. Michael J. Weber, Ph.D. Peter A. Humphrey, M.D.,Ph.D. University of Southern California Jeffrey Milbrandt,M.D.,Ph.D. $100,000 University of Washington Nobuyuki Oyama, M.D.,Ph.D. Donald G. Skinner, M.D. $7,873,220 Timothy L. Ratliff,Ph.D. Arthur Camerman,Ph.D. Brian K. Suarez,Ph.D. University of Tampere (Finland) Martin A. Cheever, M.D. $300,000 Leroy Hood,M.D.,Ph.D. Wayne State University Tapio Visakorpi,M.D.,Ph.D. Gail Jarvik,M.D.,Ph.D. $350,000 Paul H.Lange,M.D. Michael L. Cher, M.D. University of Tennessee Alvin Liu,Ph.D. Keneth V. Honn,Ph.D. $150,000 Robert L. Vessella,Ph.D. Harper Hospital Jeffrey Gingrich,M.D. J. Edson Pontes,M.D. University of Wisconsin University of Texas $3,875,000 Weizmann Institute of Science (Israel) $10,917,000 David A. Boothman,Ph.D. $1,625,000 Health Science Center at San Antonio Chawnshang Chang, Ph.D. Avri Ben-Ze’ev, Ph.D. Susan Padalecki,Ph.D. David F.Jarrard,M.D. Hadassa Degani,Ph.D. Douglas G. McNeel,M.D.,Ph.D. The M.D.Anderson Cancer Center Zelig Eshhar, Ph.D. George Wilding, M.D. Wadih Arap, M.D.,Ph.D. Benjamin Geiger, Ph.D. Donald T.Witiak,Ph.D. Danai Daliani,M.D. Yitzhak Koch,Ph.D. Yoram Salomon,Ph.D. John DiGiovanni,Ph.D. Urological Sciences Rony Seger, Ph.D. Isaiah J. Fidler, D.V.M.,Ph.D. Research Foundation Yechiel Shai,Ph.D Sue-Hwa Lin,Ph.D. $100,000 Yosef Shaul,Ph.D. Christopher J. Logothetis,M.D. Leonard S. Marks,M.D. David J.McConkey, Ph.D. David Wallach,Ph.D. Yosef Yarden,Ph.D. Timothy J.McDonnell,M.D.,Ph.D. Utah State Cancer Registry Yehiel Zick,Ph.D. Nora M. Navone,M.D.,Ph.D. $183,420 Christos N. Papandreou,M.D.,Ph.D. Janet Stanford,M.D. Yale University Andrew C. von Eschenbach,M.D. $200,000 Christopher G. Wood,M.D. Vanderbilt University Craig M. Crews,Ph.D. $350,000 Southwestern Medical Center, Dallas Sam Chang, M.D. Jerry W. Shay, Ph.D. Robert Matusik,Ph.D. University of Toronto (Canada) Joseph A. Smith,Jr.,M.D. $350,000

37 Leadership

Presidential Board Board of Directors Earle Mack Senior Partner Michael Milken The Mack Company Chairman Prostate Cancer Foundation Shmuel Meiter Director Merv Adelson Aurec Group Chairman East West Venture Group Lori Milken Vice President Gerald Ford James Blair Prostate Cancer Foundation General Partner Domain Associates Nelson Peltz Chairman and Chief Helene Brown Executive Officer Director Community Triarc Companies, Inc. Applications of Research University of California, Lynda Resnick Los Angeles Vice Chairman Roll International S. Ward (Trip) Casscells III,M.D. Jimmy Carter John Edward Tyson Bert Roberts Distinguished Professor of Consultant Medicine and Vice President of Biotechnology Richard Sandler University of Texas HSC Partner, Maron and Sandler at Houston Executive Vice President Milken Family Foundation David Ederer Chairman Lorraine Spurge Ederer Investment Company Managing Director Ronald Reagan Metropolitan West Financial Sue Gin Chairman and Chief Michael L. Tarnopol Executive Officer Vice Chairman Flying Food Group,Inc. Bear, Stearns & Co. Inc.

Robert Voss The Reverend Rosey Grier President Milken Family Foundation Fox Packaging Company Andrew Grove Jerry Weintraub Chairman George H. W. Bush President Intel Corporation Jerry Weintraub Productions Stuart Holden,M.D. Elaine Wynn Director Co-Chief Executive Officer Cedars-Sinai Louis Wynn Resorts Warschaw Prostate Cancer Center Warschaw, Robertson, Law Families Stanley Zax Chair in Prostate Cancer Chairman and President Cedars-Sinai Medical Center Zenith National Insurance Corporation

Bill Clinton David Koch Executive Vice President Koch Industries

38 Executive Officers Honorary Board Sandy Koufax Tommy Lasorda Leslie D.Michelson Ken Aretsky Tom Laughlin Vice Chairman and Edward Asner Norman Lear Chief Executive Officer Anne Bancroft Marv Levy Warren Beatty Carl Lindner Debbie Bohnett Harry Belafonte Robert Linton Executive Vice President, Samuel Belzberg Marilyn McCoo Marketing and Development Metuka Benjamin Lowell Milken Fred Biletnikoff Avram Miller Howard Soule, Ph.D. Pat Boone Jerry Monkarsh Executive Vice President Mel Brooks Robert Novak and Chief Science Officer John S. Chalsty Arnold Palmer Tony Coelho Claudia Peltz Stuart Holden,M.D. Jim Colbert Sidney Poitier Chief Medical Officer Bill Cosby Charlie Rose Michael B.Kaiserman Jamie B.Coulter Gen.H. Norman Schwarzkopf Chief Development Officer Billy Davis,Jr. Marvin Shanken Alan Dershowitz Sen. Brad Sherman Gregg S. Britt Sen. Robert Dole Neil Simon Senior Vice President, Clint Eastwood Sen. Ted Stevens Biopharmaceutical Research Sen. Dianne Feinstein Louis W. Sullivan,M.D. and Development Irving Feintech Allan Tessler David Foster William H. Tilley Scott Harvey Emil Frei III,M.D. Joe Torre Senior Vice President, Howard Gittis Clyde Turner Corporate Alliances Whoopi Goldberg Tracey Ullman Berry Gordy Robert Wagner Jan Haber Robert Goulet Rep. Maxine Waters Manager, Special Events General Alexander Haig Bob Watson Monty Hall Will Weinstein Alan Hassenfeld Jerry West Quincy Jones Stephen Wynn Hamilton Jordan Bud Yorkin Joseph Kanter Neal Kassell,M.D. Sidney Kimmel Larry King John W. Kluge Beth Kobliner

39 The Pros t a t e Can c er Fou n d a ti o n • Funds innovat ive res e a r ch that leads to bett er trea tm en t s . • Puts money in researchers’ hands quickly. • Brings together leading academic scientists with biotech and pharmaceutical companies and government leaders and researchers. • Sup ports a cons o rtium of the natio n’s leading cancer cent ers. • Leads public awareness campaigns about prostate cancer. • Gives men and their families hope for better, longer lives.

We Need You Three Ways to Donate Other Gift Suggestions

The Prostate Cancer Foundation Please mail your check to: •Assets or property including welcomes your help and support in real estate. Prostate Cancer Foundation our mission to find better treat- 1250 Fourth Street • Bequest — include a gift to PCF ments and a cure for advan c ed Santa Monica, California 90401 in your will. pros t a t e cancer. Make your check payable to • Securities. the Prostate Cancer Foundation. •Name the PCF as the primary or To make an online contribution, contingent beneficiary on a life please visit our web site: insurance policy. www.prostatecancerfoundation.org We will be happy to work with you To make a credit card donation call and your advisors to arrange a gift 80 0 . 7 5 7 . 2 8 7 3 . that meets the needs of you and your family. Thank you for your generous support. Memorial or Tribute Gifts For additional information,please Honor the memory of a loved one ca l l us at 800.757.2873 or e-mail us at or celebrate the accomplishment [email protected]. of a friend or family member by helping others. Make a memorial or tribute gift and the PCF will send an acknowledgement card to the family of the honoree.

The chart on page 6 inc ludes the most recently reported annual results for the following philanthropies: Alzheimer’s and Related Disorders Association, American Cancer Society, American Foundation for AIDS Research, American Heart Association, American Lung Association, Arthritis Foundation, Christopher Reeve Paralysis Foundation, Juvenile Diabetes Research Foundation, Leukemia and Lymphoma Foundation, March of Dimes, Muscular Dystrophy Association, National Kidney Foundation, National Multiple Sclerosis Society and Susan G. Komen Breast Cancer Foundation.

40 1250 Fourth Street Santa Monica, California 90401 Tel 310.570.4700 Fax 310.570.4701 www.prostatecancerfoundation.org